Cliff Asness's SMMT Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 443,757 shares of Summit Therapeutics Inc. (SMMT) worth $8.11 M, representing 0.00% of the portfolio. First purchased in 2023-Q3, this medium-term investment has been held for 10 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in SMMT, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2025, adding 170,386 shares. Largest reduction occurred in Q2 2025, reducing 43,311 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Summit Therapeutics (SMMT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Summit Therapeutics (SMMT) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +85,887 | Add 24.00% | 443,757 | $18.28 |
| Q4 2025 | +170,386 | Add 90.88% | 357,870 | $17.31 |
| Q3 2025 | +165,172 | Add 740.28% | 187,484 | $20.66 |
| Q2 2025 | -43,311 | Reduce 66.00% | 22,312 | $21.28 |
| Q1 2025 | +3,134 | Add 5.02% | 65,623 | $19.29 |
| Q4 2024 | -6,029 | Reduce 8.80% | 62,489 | $17.84 |
| Q3 2024 | +6,404 | Add 10.31% | 68,518 | $21.90 |
| Q2 2024 | +62,114 | New Buy | 62,114 | $7.80 |
| Q4 2023 | -19,225 | Sold Out | 0 | $0.00 |
| Q3 2023 | +19,225 | New Buy | 19,225 | $1.87 |
Cliff Asness's Summit Therapeutics Investment FAQs
Cliff Asness first purchased Summit Therapeutics Inc. (SMMT) in Q3 2023, acquiring 19,225 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Summit Therapeutics Inc. (SMMT) for 10 quarters since Q3 2023.
Cliff Asness's largest addition to Summit Therapeutics Inc. (SMMT) was in Q4 2025, adding 357,870 shares worth $6.19 M.
According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 443,757 shares of Summit Therapeutics Inc. (SMMT), valued at approximately $8.11 M.
As of the Q1 2026 filing, Summit Therapeutics Inc. (SMMT) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Summit Therapeutics Inc. (SMMT) was 443,757 shares, as reported at the end of Q1 2026.